Pharmacokinetics

macitentan

Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...

TevaImpax generic Wellbutrin XL 300mg pulled from US market on non-bioequivalence grounds

Following a review of new data, the US Food and Drug Administration says these indicate that Budeprion XL 300mg (bupropion hydrochloride extended-release tablets), a generic version of UK pharma giant...

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. today announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR h...

Pregabalin CR Meets Goal in Fibromyalgia, Not Seizure Trial

Pfizer reports top-line results from 2 phase 3 trials of a once-daily controlled-release formulation of pregabalin. Medscape Medical News

Rapid Relief of Neuropathic Pain With Pregabalin in SCI

A post hoc analysis of pivotal trials shows that pregabalin relieves pain in spinal cord injury within 2 days of start of treatment. Medscape Medical News

Duloxetine Beats Pregabalin for Diabetic Neuropathy

In the largest trial for diabetic neuropathic pain, analgesia was better with duloxetine than with pregabalin. Combining the 2 drugs was as effective as raising the doses for resistant patients. Med...

Pfizer follows CR pregabalin epilepsy failure with success in Phase III fibromyalgia trial

Pfizer has fared better in the second out of three Phase III trials of its controlled-release (CR) formulation of the GABA analogue, pregabalin, this time in the indication of fibromyalgia. The compa...

CORRECTED-BRIEF-Pfizer says fibromyalgia drug met main goal in late-stage study

(Corrects headline to say study met main goal, not failed it) Nov 19 (Reuters) - Pfizer : * Reports top-line results of a phase 3 study evaluating pregabalin controlled-release as treatment for patie...

Pfizer Phase 3 pregabalin study fails to meet primary endpoint

Pfizer Phase 3 study of pregabalin controlled-release (CR) formulation has failed to meet the primary endpoint of reducing the frequency of seizures in epilepsy patients.

The Absorption Profile of Pregabalin in Chronic Pancreatitis.

It was recently shown that pregabalin decreased pain associated with chronic pancreatitis. It is well known that pancreatitis patients suffer from fat malabsorption with accompanying diarrhoea due to...

A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures.

PURPOSE: This study assessed the comparative efficacy of pregabalin for refractory partial seizures. METHODS: Four-hundred and thirty-four patients with partial seizures were randomized to pregabalin,...

Bioequivalence assessment of a pregabalin capsule and oral solution in fasted healthy volunteers: a randomized, crossover study.

Objective: To determine the oral bioavailability of a pregabalin capsule relative to a pregabalin solution. Methods: This was an open-label, randomized, crossover study in 12 healthy volunteers. Pharm...

Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat.

Pregabalin (Lyrica™) is a structural analog of γ-aminobutyric acid (GABA) and is approved by the FDA for partial epilepsy, neuropathic pain and generalized anxiety disorders. Pregabalin also reduce...

Retrospective Chart Review of Duloxetine and Pregabalin in the Treatment of Painful Neuropathy.

ABSTRACT The primary aims of our study were to compare pregabalin and duloxetine in a neuromuscular clinic for diabetic neuropathic pain (DPN) and to study the effect of these medications in cryptogen...